Literature DB >> 25560841

Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2.

E Gane1, D Kershenobich, C Seguin-Devaux, P Kristian, I Aho, O Dalgard, I Shestakova, P Nymadawa, S Blach, S Acharya, A C Anand, M I Andersson, V Arendt, P Arkkila, O Baatarkhuu, K Barclay, Z Ben-Ari, C Bergin, F Bessone, N Blokhina, C R Brunton, G Choudhuri, V Chulanov, L Cisneros, E A Croes, Y A Dahgwahdorj, J R Daruich, N R Dashdorj, D Davaadorj, R J de Knegt, M de Vree, A C Gadano, E Gower, W Halota, A Hatzakis, C Henderson, P Hoffmann, J Hornell, D Houlihan, S Hrusovsky, P Jarčuška, K Kostrzewska, M Leshno, Y Lurie, A Mahomed, N Mamonova, N Mendez-Sanchez, J Mossong, S Norris, E Nurmukhametova, M Oltman, J Oyunbileg, Ts Oyunsuren, G Papatheodoridis, N Pimenov, M Prins, P Puri, S Radke, A Rakhmanova, H Razavi, K Razavi-Shearer, H W Reesink, E Ridruejo, R Safadi, O Sagalova, J F Sanchez Avila, R Sanduijav, V Saraswat, I Schréter, S R Shah, A Shevaldin, O Shibolet, M O Silva, S Sokolov, M Sonderup, K Souliotis, C W Spearman, T Staub, C Stedman, E A Strebkova, D Struck, V Sypsa, K Tomasiewicz, L Undram, A J van der Meer, D van Santen, I Veldhuijzen, F G Villamil, S Willemse, E Zuckerman, F R Zuure, N Prabdial-Sing, R Flisiak, C Estes.   

Abstract

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries, and the relative impact of two scenarios was considered: (i) increased treatment efficacy while holding the treated population constant and (ii) increased treatment efficacy and increased annual treated population. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. In most countries, the annual treated population had to increase several fold to achieve the largest reductions in HCV-related morbidity and mortality. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. In most of the studied countries, the majority of patients were born between 1945 and 1985.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  HCV; diagnosis; disease burden; epidemiology; hepatitis C; incidence; mortality; prevalence; scenarios; treatment

Mesh:

Substances:

Year:  2015        PMID: 25560841     DOI: 10.1111/jvh.12352

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  17 in total

Review 1.  Tackling the Hepatitis C Disease Burden in Punjab, India.

Authors:  Radha K Dhiman; Sandeep Satsangi; Gagandeep S Grover; Pankaj Puri
Journal:  J Clin Exp Hepatol       Date:  2016-09-07

2.  Efficacy and safety of elbasvir/grazoprevir treatment for Chinese patients with hepatitis C virus genotype 1b: a retrospective study.

Authors:  Juan Li; Guangming Li; Juanxia Wang; Rui Zhao; Jingjing He; Liang Wang; Lingyi Zhang
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

3.  Prevalence and knowledge of hepatitis C in a middle-aged population, Dunedin, New Zealand.

Authors:  Jane Vermunt; Margaret Fraser; Peter Herbison; Anna Wiles; Martin Schlup; Michael Schultz
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

4.  Facilitating treatment of HCV in primary care in regional Australia: closing the access gap.

Authors:  Lauren White; Ali Azzam; Lauren Burrage; Clare Orme; Barbara Kay; Sarah Higgins; Simone Kaye; Andrew Sloss; Jennifer Broom; Nicola Weston; Jonathan Mitchell; James O'Beirne
Journal:  Frontline Gastroenterol       Date:  2018-10-24

Review 5.  Economic evaluation of HCV testing approaches in low and middle income countries.

Authors:  Jake R Morgan; Maria Servidone; Philippa Easterbrook; Benjamin P Linas
Journal:  BMC Infect Dis       Date:  2017-11-01       Impact factor: 3.667

Review 6.  The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention.

Authors:  Natasha K Martin; Peter Vickerman; Gregory J Dore; Matthew Hickman
Journal:  Curr Opin HIV AIDS       Date:  2015-09       Impact factor: 4.283

Review 7.  Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes.

Authors:  Arnolfo Petruzziello; Samantha Marigliano; Giovanna Loquercio; Anna Cozzolino; Carmela Cacciapuoti
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

Review 8.  Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe.

Authors:  Arnolfo Petruzziello; Samantha Marigliano; Giovanna Loquercio; Carmela Cacciapuoti
Journal:  Infect Agent Cancer       Date:  2016-10-12       Impact factor: 2.965

9.  Attempt to calculate the prevalence and features of chronic hepatitis C infection in Tuscany using administrative data.

Authors:  Caterina Silvestri; Simone Bartolacci; Pasquale Pepe; Mirko Monnini; Fabio Voller; Francesco Cipriani; Cristina Stasi
Journal:  World J Gastroenterol       Date:  2016-11-28       Impact factor: 5.742

10.  Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries.

Authors:  A M Falla; A A Ahmad; E Duffell; T Noori; I K Veldhuijzen
Journal:  BMC Infect Dis       Date:  2018-01-16       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.